Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 2
2019 1
2020 4
2021 6
2022 3
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Targeted therapy for pediatric low-grade glioma.
Pérez JPM, Muchart J, López VS, Capella MS, Salvador N, Jaume SP, Martínez OC, La Madrid AM. Pérez JPM, et al. Among authors: jaume sp. Childs Nerv Syst. 2021 Aug;37(8):2511-2520. doi: 10.1007/s00381-021-05138-3. Epub 2021 Apr 17. Childs Nerv Syst. 2021. PMID: 33864514
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.
Pascual-Pasto G, Resa-Pares C, Castillo-Ecija H, Aschero R, Baulenas-Farres M, Vila-Ubach M, Burgueño V, Balaguer-Lluna L, Cuadrado-Vilanova M, Olaciregui NG, Martinez-Velasco N, Perez-Jaume S, de Alava E, Tirado OM, Lavarino C, Mora J, Carcaboso AM. Pascual-Pasto G, et al. Among authors: perez jaume s. Biochem Pharmacol. 2023 Feb;208:115408. doi: 10.1016/j.bcp.2022.115408. Epub 2023 Jan 2. Biochem Pharmacol. 2023. PMID: 36603685
Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma.
Aschero R, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Vilanova MC, Perez-Jaume S, Pascual-Pasto G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F, Chantada GL. Aschero R, et al. Among authors: perez jaume s. Pediatr Blood Cancer. 2024 Jan;71(1):e30717. doi: 10.1002/pbc.30717. Epub 2023 Oct 9. Pediatr Blood Cancer. 2024. PMID: 37814421
Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Castillo-Ecija H, Pascual-Pasto G, Perez-Jaume S, Resa-Pares C, Vila-Ubach M, Monterrubio C, Jimenez-Cabaco A, Baulenas-Farres M, Muñoz-Aznar O, Salvador N, Cuadrado-Vilanova M, Olaciregui NG, Balaguer-Lluna L, Burgueño V, Vicario FJ, Manzanares A, Castañeda A, Santa-Maria V, Cruz O, Celis V, Morales La Madrid A, Garraus M, Gorostegui M, Vancells M, Carrasco R, Krauel L, Torner F, Suñol M, Lavarino C, Mora J, Carcaboso AM. Castillo-Ecija H, et al. Among authors: perez jaume s. J Pathol Clin Res. 2021 Jul;7(4):338-349. doi: 10.1002/cjp2.210. Epub 2021 Apr 9. J Pathol Clin Res. 2021. PMID: 33837665 Free PMC article.
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda A, Garraus M, Lopez-Miralles S, Mora J. Muñoz JP, et al. Among authors: perez jaume s. Cancers (Basel). 2023 Oct 3;15(19):4837. doi: 10.3390/cancers15194837. Cancers (Basel). 2023. PMID: 37835531 Free PMC article.
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.
Mora J, Castañeda A, Gorostegui M, Varo A, Perez-Jaume S, Simao M, Muñoz JP, Garraus M, Larrosa C, Salvador N, Lavarino C, Krauel L, Mañe S. Mora J, et al. Among authors: perez jaume s. Cancers (Basel). 2023 Apr 28;15(9):2535. doi: 10.3390/cancers15092535. Cancers (Basel). 2023. PMID: 37174002 Free PMC article.
Vitamin D Status in Children With High-risk Neuroblastoma.
Izurieta-Pacheco AC, Sangrós-Gimenez A, Martínez-Garcia E, Perez-Jaume S, Mora J, Gorostegui-Obanos M. Izurieta-Pacheco AC, et al. Among authors: perez jaume s. J Pediatr Hematol Oncol. 2023 Nov 1;45(8):e953-e958. doi: 10.1097/MPH.0000000000002762. Epub 2023 Oct 2. J Pediatr Hematol Oncol. 2023. PMID: 37779236
Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients.
Cuadrado-Vilanova M, Liu J, Paco S, Aschero R, Burgueño V, Sirab N, Pascual-Pasto G, Correa G, Balaguer-Lluna L, Castillo-Ecija H, Perez-Jaume S, Muñoz-Aznar O, Roldan M, Suñol M, Schaiquevich P, Aerts I, Doz F, Cassoux N, Lubieniecki F, Benitez-Ribas D, Lavarino C, Mora J, Chantada GL, Catala-Mora J, Radvanyi F, Carcaboso AM. Cuadrado-Vilanova M, et al. Among authors: perez jaume s. J Pathol. 2022 Jul;257(3):327-339. doi: 10.1002/path.5893. Epub 2022 Apr 13. J Pathol. 2022. PMID: 35254670
A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
Gómez S, Garrido-Garcia A, Garcia-Gerique L, Lemos I, Suñol M, de Torres C, Kulis M, Pérez-Jaume S, Carcaboso ÁM, Luu B, Kieran MW, Jabado N, Kozlenkov A, Dracheva S, Ramaswamy V, Hovestadt V, Johann P, Jones DTW, Pfister SM, Morales La Madrid A, Cruz O, Taylor MD, Martin-Subero JI, Mora J, Lavarino C. Gómez S, et al. Among authors: perez jaume s. Clin Cancer Res. 2018 Mar 15;24(6):1355-1363. doi: 10.1158/1078-0432.CCR-17-2243. Epub 2018 Jan 19. Clin Cancer Res. 2018. PMID: 29351917
27 results